Loading stock data…
PROK
$1.88-0.05 (-2.59%)
Market ClosedLast close May 4
ProKidney Corp., a clinical-stage biotechnology company, engages in the development of cell therapies for the treatment of chronic kidney diseases in the United States.
Historical Price
Price (Candle)
50-Day SMA
200-Day SMA
Whystock Brain
The Narrative
ProKidney Corp. in the Healthcare sector is trading at $1.88. The stock is currently 74% below its 52-week high of $7.13, remaining 21.3% below its 200-day moving average. Technical signals show neutral RSI of 48 and bearish MACD signal, explaining why PROK maintains its current current market pressure. The Whystock Score of 35/100 signals elevated caution as indicators diverge.
Ecosystem Influences
Neutral momentum (RSI 48) — price action in range
Long-term trend bearish (Price vs 200-day SMA)
Macro-economic sensitivity to interest rate and inflation shifts
Loading Financials...
Peer Comparison
JNJUNHPFE
Whystock Valuation Model
Whystock fair value is estimated using a trailing P/E model adjusted for return on equity: Fair P/E = 18 + (ROE × 20). Fair Value = (Current Price ÷ Trailing P/E) × Fair P/E. A base P/E of 18 represents a typical market multiple, scaled upward for companies that earn high returns on equity. The result is a theoretical "normalised" price — not a price target or investment advice. Large deviations are common for high-growth or loss-making companies.
Current Price$1.88
Potential Upside
5%
Whystock Fair Value$1.97
Price
UndervaluedFair ValueOvervalued
Simplified model based on P/E and ROE. Not a substitute for full valuation analysis. Data may be delayed. See our Terms.
Fundamentals
ProKidney Corp., a clinical-stage biotechnology company, engages in the development of cell therapies for the treatment of chronic kidney diseases in the United States. The company develops rilparencel, a cell therapy with autologous selected renal c...
Market Cap
Total dollar market value of a company's outstanding shares of stock (Price * Shares).
$631.10M
P/E Ratio
Priced for growth. Investors expect sustained double-digit expansion.
-
Beta
High-beta play. Expect amplified moves vs. the broad market.
1.86
Div Yield
Low to zero yield. Return is entirely dependent on price appreciation.
0.00%
ROE
Average efficiency. Growth may require heavy reinvestment.
6.82%
Volume
Today's trading volume
518,217
Recent News
ProKidney (PROK) Appoints Greg Madison as CCO to Lead Commercial Strategy for Rilparencel
ProKidney Corp. (NASDAQ:PROK) is one of the best biotech penny stocks to buy in 2026. On March 25, ProKidney appointed Greg Madison as Chief Commercial Officer, a move aimed at preparing the company for the potential launch of its lead cell therapy, rilparencel. Reporting to CEO Bruce Culleton, M.D., Madison is tasked with shaping the […]
April 2026 Penny Stock Highlights
Over the last 7 days, the U.S. market has risen by 1.9%, contributing to a 24% increase over the past year, with earnings projected to grow by 15% annually in the coming years. In such a thriving market, identifying stocks with solid financial foundations and growth potential is key for investors looking to capitalize on emerging opportunities. While penny stocks may seem like an outdated concept, they continue to offer access to smaller or newer companies that can provide both affordability...
What Makes ProKidney Corp. (PROK) So Attractive
ProKidney Corp. (NASDAQ:PROK) is one of the 10 best penny stocks that could triple your money. On March 19, ProKidney Corp. (NASDAQ:PROK) announced fourth-quarter revenue of $893,000 against consensus estimates of $600,000. The company provided updates on its clinical progress and strategic priorities for advancing rilparencel through regulatory pathways. Chief Executive Officer Bruce Culleton stated […]
Korro Bio, Inc. (KRRO) Reports Q4 Loss, Lags Revenue Estimates
Korro Bio, Inc. (KRRO) delivered earnings and revenue surprises of -175.08% and -13.87%, respectively, for the quarter ended December 2025. Do the numbers hold clues to what lies ahead for the stock?
Aquestive Therapeutics (AQST) Reports Q4 Loss, Misses Revenue Estimates
Aquestive Therapeutics (AQST) delivered earnings and revenue surprises of -100.00% and -2.64%, respectively, for the quarter ended December 2025. Do the numbers hold clues to what lies ahead for the stock?